Literature DB >> 9294527

Adrenal insufficiency as a manifestation of disseminated non-Hodgkin's lymphoma.

N T Levy1, W F Young, T M Habermann, J G Strickler, J A Carney, A W Stanson.   

Abstract

OBJECTIVE: To analyze the clinical characteristics, laboratory features, and outcome in five patients who had biochemically proven adrenal insufficiency attributable to pathologically confirmed non-Hodgkin's lymphoma (NHL).
MATERIAL AND METHODS: We retrospectively reviewed the medical records of all patients at Mayo Clinic Rochester during the period from 1976 to 1994 to identify those with both NHL, as listed in the surgical pathology tissue registry, and adrenal insufficiency. Histologically, the patients were classified on the basis of the working formulation and the revised European-American lymphoma classification.
RESULTS: Three patients had diffuse large cell NHL, one patient had small noncleaved NHL, and one patient had cutaneous T-cell NHL. All five patients had stage IV disease. Adrenal insufficiency was confirmed by morning and evening determinations of serum cortisol levels and cosyntropin stimulation tests. All patients demonstrated loss of circadian rhythm. The median age of the patients was 77 years (range, 60 to 89). Three of the five patients died without treatment from 5 to 22 days after assessment. One patient died of a cerebrovascular accident. Despite initiation of chemotherapy, two patients died of progressive NHL at 7 weeks and 7 months.
CONCLUSION: In our experience, biochemically proven adrenal insufficiency in patients with NHL is a manifestation of clinically advanced disease in elderly patients. A stepwise diagnostic approach is critical for the appropriate management of such patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294527     DOI: 10.4065/72.9.818

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes.

Authors:  Deanna M Santer; Alice E Wiedeman; Thomas H Teal; Pradipta Ghosh; Keith B Elkon
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  Cutaneous T-cell lymphoma with adrenal insufficiency.

Authors:  J F Blaikley; P Atkinson; M K Almond
Journal:  J R Soc Med       Date:  2003-10       Impact factor: 5.344

3.  Diffuse large B-cell lymphoma of the adrenal gland: a rare cause of primary adrenal insufficiency.

Authors:  Adriana de Sousa Lages; Margarida Bastos; Patrícia Oliveira; Francisco Carrilho
Journal:  BMJ Case Rep       Date:  2016-03-18

4.  Mainly adrenal gland involving NK/T-cell nasal type lymphoma diagnosed with delay due to mimicking adrenal hemorrhage.

Authors:  Seon Mee Kang; Woong Ji Kim; Kyung Ae Lee; Hong Sun Baek; Tae Sun Park; Heung Yong Jin
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

5.  A case report of primary unilateral adrenal NK/T cell lymphoma: good clinical outcome with trimodality treatment.

Authors:  Liu Hu; Weimin Xu; Mingwei Wang; Pan Wang; Guang Han; Chi Lin
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

6.  Primary adrenal extranasal NK/T cell lymphoma with subcutaneous involvement demonstrated on FDG PET/CT: A clinical case report.

Authors:  Ping Dong; Li Wang; Guohua Shen; Lin Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

7.  Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).

Authors:  Yu Ri Kim; Jin Seok Kim; Yoo Hong Min; Dok Hyunyoon; Ho-Jin Shin; Yeung-Chul Mun; Yong Park; Young Rok Do; Seong Hyun Jeong; Joon Seong Park; Sung Yong Oh; Suee Lee; Eun Kyung Park; Joung-Soon Jang; Won-Sik Lee; Hwe-Won Lee; Hyeonseok Eom; Jae-Sook Ahn; Jae-Heon Jeong; Sun Kyung Baek; Seok Jin Kim; Won Seog Kim; Cheolwon Suh
Journal:  J Hematol Oncol       Date:  2012-08-13       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.